Observation on efficacy of irbesartan tablets combined with amlodipine besylate tablets in the treatment of refractory hypertension
Objective To explore the effect of irbesartan tablets combined with amlodipine besylate tablets in the treatment of patients with refractory hypertension.Results A total of 80 patients with refractory hypertension were randomly divided into a control group and an observation group,with 40 patients in each group.The control group was treated with amlodipine besylate tablet alone,and the observation group was treated with irbesartan tablet simultaneously.Patients in both groups were compared in terms of clinical treatment effect,blood pressure(systolic blood pressure,diastolic blood pressure),renal function indicators[uric acid(UA),blood urea nitrogen(BUN),serum creatinine(Scr)],endothelial function indicators[nitric oxide(NO),endothelin-1(ET-1),angiotensin(Ang)],serum inflammatory factors[tumor necrosis factor-α(TNF-α),serum interleukin-6(IL-6),serum interleukin-1β(IL-1β)]before and after treatment,and incidence of adverse reactions.Results The total effective rate of the observation group was 97.50%,which was higher than the control group's 80.00%(P<0.05).After treatment,the systolic blood pressure and diastolic blood pressure decreased in both groups;the observation group had systolic blood pressure of(131.29±19.83)mm Hg(1 mm Hg=0.133 kPa)and diastolic blood pressure of(74.29±11.39)mm Hg,which were lower than(149.39±20.82)and(82.79±11.73)mm Hg in the control group(P<0.05).After treatment,UA,BUN and Scr decreased in both groups;the observation group had UA of(324.29±28.39)μmol/L,BUN of(5.38±1.02)mmol/L and Scr of(62.93±4.92)μmol/L,which were lower than(343.92±29.39)μmol/L,(6.45±0.82)mmol/L and(70.72±4.05)μmol/L in the control group(P<0.05).After treatment,NO increased,ET-1 and Ang decreased in both groups;the observation group had higher NO of(132.31±10.39)μmol/L than(113.94±10.28)μmol/L in the control group;the observation group had ET-1 of(63.23±7.31)ng/L and Ang of(49.23±8.19)ng/L,which were lower than(68.34±6.91)and(55.49±8.93)ng/L in the control group(P<0.05).After treatment,TNF-α,IL-6 and IL-1β decreased in both groups;the observation group had TNF-α of(27.39±3.92)ng/L,IL-6 of(79.34±10.39)ng/L and IL-1β of(328.39±19.34)ng/ml,which were lower than(34.45±4.01)ng/L,(98.39±9.34)ng/L and(384.29±20.94)ng/ml in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with refractory hypertension,administration of irbesartan tablets and amlodipine besylate tablets can significantly improve the total effective rate,reduce blood pressure detection value,improve the level of renal function and endothelial function,and reduce the degree of inflammatory response,and has a certain safety.
万方数据
维普
